Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs). Ivonescimab remains the ...
While they have been around for some years, ADCs – which pair antibodies with a drug payload ... developed by Iconic Therapeutics – called ICON-2 – which targets the tissue factor (TF ...
ImmunoPrecise Antibodies (IPA) announces a strategic partnership with a leading biotechnology company with a multi-billion-dollar market ...
Taiho Pharmaceutical Co., Ltd.Araris Biotech AGTaiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback